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The mouse mammary gland develops postnatally under the control
of female reproductive hormones. Estrogens and progesterone
trigger morphogenesis by poorly understood mechanisms acting on
a subset of mammary epithelial cells (MECs) that express their
cognate receptors, estrogen receptor α (ERα) and progesterone
receptor (PR). Here, we show that in the adult female, progesterone
drives proliferation of MECs in two waves. The first, small wave,
encompasses PR(+) cells and requires cyclin D1, the second, large
wave, comprises mostly PR(−) cells and relies on the tumor necrosis
factor (TNF) family member, receptor activator of NF-κB-ligand
(RANKL). RANKL elicits proliferation by a paracrinemechanism. Abla-
tion of RANKL in the mammary epithelium blocks progesterone-
induced morphogenesis, and ectopic expression of RANKL in MECs
completely rescues the PR−/− phenotype. Systemic administration of
RANKL triggers proliferation in theabsenceofPR signaling, and injec-
tion of a RANK signaling inhibitor interferes with progesterone-
induced proliferation. Thus, progesterone elicits proliferation by a
cell-intrinsic and a, more important, paracrine mechanism.
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Lifetime exposure to reproductive hormones, in particularestrogens and progesterone, affects the risk of breast cancer, a
complex disease that is under hormonal control (1). The same
hormones also control development of the mouse mammary
gland, most of which occurs after birth. In response to ovarian
estrogen secretion at puberty, the rudimentary ductal system
extends from the nipple area into the fat pad through dichotomous
branching. The complexity of the milk duct system increases
through the formation of side branches triggered by cyclic changes
in estrogen and progesterone secretion during adulthood. Side
branching is enhanced during the first half of pregnancy. Sub-
sequently, saccular outpouchings, alveoli, bud off the ducts and
differentiate to become sites of milk production during lactation.
Once pups are weaned, the mammary gland returns to a pre-
pregnancy state through involution.
Tissue recombination experiments with mammary epithelium
frommice with germ-line deletion of the estrogen receptor (ER) α
(2), the progesterone receptor (PR) (3), or the prolactin receptor
(PrlR) (4) revealed that epithelial intrinsic ERα is required for
ductal elongation (5), PR for ductal side branching (6), and PrlR
for alveologenesis and differentiation into milk-producing cells
(7). PRs are composed of two proteins that are expressed from a
single gene as a result of transcription from two alternative pro-
moters (8), both of which are expressed in the mouse mammary
gland (9). Deletion of either PR-A or PR-B from the mouse germ
line revealed that PR-B is specifically required formammary gland
development (3, 10, 11).
The mechanisms by which hormones induce proliferation in
vivo are poorly understood. The mammary epithelium consists of
an inner layer of luminal cells that are surrounded by basal cells
juxtaposed to the basal lamina. Some of these are in suprabasal
position and thought to comprise progenitor cells others are
spindle shaped and called myoepithelial cells because they exhibit
features of smooth muscle cells. The receptors for both steroid
hormones are expressed in about 30%of the luminal cells andhave
been shown to colocalize in the human breast (12). Colabeling
studies in humans and rodents revealed that most of the pro-
liferating cells are hormone receptor negative (12–14). Chimeric
epithelia in which ERα- or PR-deficient cells were mingled with
WT cells showed that the mutant cells participated actively in
ductal growth in the context of surrounding WT MEC (5, 6).
The tumor necrosis family (TNF)member, receptor activator of
NF-κB-ligand (RANKL), is important for osteoclast differ-
entiation and lymph-node organogenesis (15) andwas shown to be
required for pregnancy-induced lactational mammary gland
development (16) and implicated upstream of cyclin D1 in mam-
mary epithelial cells (MECs) acting via the IKKα subunit of IκB
kinase (17). Ectopic expression of RANKL in the mammary epi-
thelium was shown to elicit ductal side branching and alveolo-
genesis (18); similarly, overexpression of the cognate receptor
RANKresulted in increasedproliferation (19).Here,we show that
progesterone induces proliferation of a subset of PR-positive (+)
MECs by a cell-autonomous, cyclin D1-dependent mechanism
and a larger wave of proliferation by a paracrine, RANKL-
dependent mechanism.
Results
Two Waves of Progesterone-Induced Proliferation. To examine cell
proliferation induced by ovarian steroids, we administered 17-
β-estradiol and progesterone to adult mice that had been ovar-
iectomized 10 days earlier to deplete their endogenous steroids,
and pretreated with 17-β-estradiol for 24 h to restore PR expres-
sion (20).Neither vehicle, nor 17-β-estradiol alone (Fig. 1A andB)
elicited proliferation considerably above background levels as
assessed by 5′bromo-2′deoxyuridine (BrdU) labeling, but exten-
sive proliferation occurred when progesterone was added (Fig. 1A
and B), highlighting that 17-β-estradiol, a major mitogen in the
pubertal gland (21), is merely permissive for the proliferative
effects of progesterone in the adult mammary gland.
Based on previous reports that few proliferating MECs express
ERα and PR in humans and rodents (12–14), and genetic evidence
that progesterone can act by paracrine mechanisms (6), we
hypothesized that progesterone may be directly mitogenic for
some PR(+) MECs and elicit proliferation of PR(−) MECs by a
paracrinemechanism. As cell divisions elicited by directmitogenic
stimulation should occur earlier than those following paracrine
stimulation, we assessed proliferation at distinct time points. To
identify all early proliferation events, we administered BrdU
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continuously for 24 h following hormone stimulation. Anti-BrdU
staining revealed that 5% of MECs incorporated the label (Fig.
1A); double immunohistochemistry showed that most of these
were PR(+) (Fig. 1 C and E), and found in the luminal compart-
ment (Fig. 1C). Then, we pulsed mice with BrdU 46–48 h after
progesterone stimulation. Under these conditions, about 15% of
MECs incorporated the label (Fig. 1B); out of these less than 10%
were PR(+) (Fig. 1D andE). A time-course analysis revealed that
BrdU incorporation was first above background level at 18 h after
stimulation, with 3.2% of the MECs staining positive for the
labeled nucleotide. Colabeling forBrdUandPRconfirmed that up
to 24 h, almost all of the proliferatingMECswere PR(+); on day 2,
the PR(+) cell fraction represented 9.3%, and by day 5 less than
5% of the proliferating MECs (Fig. 1F). From day 2 on, pro-
liferating cells were found in luminal and subluminal locations as
well as in the myoepithelium. Proliferation peaked on day 3 with
27% of MECs incorporating BrdU (Fig. 1G). Analysis of PR(+)
and PR(−) MEC populations revealed two distinct peaks of pro-
liferation (Fig. 1G, red and blue line): a small peak of PR(+) cell
proliferation at 24 h and a large peak of PR(−) cell proliferation at
72 h. We note that the incorporation index at 48 h is higher under
repeated hormone stimulation (Fig. 1 F and G) than following a
single bolus (Fig. 1 A–E). Taken together, progesterone stim-
ulation elicits two waves of proliferation in the mammary epi-
thelium, a first small wave of PR(+) cells and a subsequent large
wave of PR(−) MECs.
Cyclin D1 and Progesterone-Induced Proliferation. Cyclin D1 is
amplified specifically in ERα(+) breast cancers and is a proges-
terone target gene in the PR(+) breast cancer cell line T47D (22).
To assess whether cyclin D1 is required in vivo for progesterone-
induced proliferation, we generatedmicewith cyclinD1−/− andWT
mammary epithelia in contralateral glands by tissue recombination.
Briefly, in 3-week-old mice, the inguinal glands can be cleared of
endogenous epithelium by surgically removing the nipple-near half
that contains the rudimentary ductal system. MECs that are intro-
duced into the remaining “cleared” fat pad will give rise to a new
ductal system. They can grow out from a piece of mammary tissue
that is implanted (23), or from single-cell suspensions injected into
the fat pad (24). To distinguish the graft from endogenous epi-
thelium inadvertently left behind, we crossed the mutant cyclin D1
allele into a transgenic strain that ubiquitously expresses green
fluorescent protein (GFP) (25) and grafted the GFP(+) donor
tissue into GFP(−) hosts. Eight weeks later, recipients were ana-
lyzed 24 or 48 h after progesterone stimulation. As expected, within
24 h of progesterone stimulation, 6–16% of WTMECs had incor-
porated BrdU (Fig. 2 B and E). The contralateral cyclin D1−/−
epithelial grafts, however, incorporated only background levels
(Fig. 2 A and E). At 48 h, BrdU incorporation indices in both
WT (Fig. 2D and F) and cyclinD1−/− epithelia were in the range of
10–24% (Fig. 2 C and F). Double immunofluorescence revealed
that among both WT and mutant MECs more than 90% of the
BrdU-incorporating cells were PR(−) (Fig. S1). Thus, cyclin D1
function is required for cell-autonomous division of PR(+) cells
induced by progesterone, but the second wave of proliferation is
cyclin D1 independent. We note that grafted epithelia in general
have higher proliferative indices than endogenous ones.
Role of RANKL in the Mammary Epithelium. Next, we sought to
identify the mediator of progesterone’s paracrine mitogenic
effects. Several factors had been implicated downstream of pro-
gesterone signaling in the mammary gland, including Wnt-4 (26),
RANKL (10, 27), Calcitonin (28), and Id4 (29). RANKLhad been
proposed as a candidate paracrine mediator based on the obser-
vation that RANKL protein was shown to be expressed in PR(+)
cells (10). Yet, analysis of RANKL-deficient mice indicated that
the cytokine is required late in pregnancy for alveologenesis and
lactogenic differentiation (16). As analysis of the mammary gland
phenotype in RANKL−/− mice may have been confounded by
systemic effects of the deletion (15), we performed mammary
Fig. 1. Progesterone induces two waves of proliferation. (A–E) Ten-week-old female mice were ovariectomized, pretreated with 17-β-estradiol 10 days later,
and then injected with vehicle, 17-β-estradiol, or 17-β-estradiol and progesterone. BrdU was administered repeatedly for analysis at 24 h (A and C) or as a
single bolus at 46 h (B and D). Bars show BrdU incorporating MECs ± SEM in different treatment groups 24 h (A) and 48 h (B) after injection (n = 3). Double
immunofluorescence after 24 h (C) and 48 h (D) of stimulation. Green, PR; red, BrdU; blue, DAPI. (Scale bar: 40 μm.) (E) Percentage of PR(+) and PR(−) cells ±
SEM among BrdU incorporating MECs 24 h and 48 h after progesterone stimulation. (F and G) Ten-week-old female mice were ovariectomized and treated
every 24 h with 17-β-estradiol and progesterone. Percentage of PR(+) and PR(−) BrdU incorporating MECs determined by double immunofluorescence; 40–400
BrdU(+) MECs counted per mouse (n = 3–4) (F). BrdU incorporation indices were determined by counting 3,000 cells per mouse (n = 3–4), and plotted over
time. Percentage of PR(+) (red) and PR(−) cells (blue) incorporating BrdU was calculated based on F (G).
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gland recombination experiments to discern the epithelial intrinsic
effects of the deletion.
Fluorescent stereomicroscopy of contralateral glands engrafted
with GFP+.RANKL−/− versus GFP+.RANKL+/+ MECs (Fig. S2
A and C) revealed that pubertal ductal outgrowth (9 weeks) was
comparable between WT and mutant grafts. At 13 weeks of age,
WT grafts gained complexity due to side branching, whereas the
RANKL−/− epithelium did not. By day 14.5 of pregnancy, WT
grafts had developed side branches and alveolar buds, whereas
RANKL−/− grafts had only bifurcated. At the end of pregnancy,
WT epithelia showed extensive alveologenesis, whereas
RANKL−/− epithelia had few side branches and alveoli (Fig. S2A–
C).Quantification of side branches at 13weeks confirmed thatWT
grafts were consistently more complex than the RANKL−/−
counterparts (Fig. S2D).
Histological analysis of the engrafted glands revealed normal
tissue structure at all stages (Fig. S2B) with immunohistochemistry
for the myoepithelial markers p63 (Fig. S2E) and smooth muscle
actin (Fig. S2F) showing normal organization of the two epithelial
layers. Morphological hallmarks of secretion, such as lipid drop-
lets, characteristic of the WT lactating gland, were sparse in the
RANKL−/− epithelium (Fig. S2 B and G). Immunostainings for
β-casein revealed the presence of this milk protein (Fig. S2G),
suggesting differentiation occurs in the absence of RANKL.
Thus, epithelial RANKL is required for mammary gland side
branching before and during pregnancy, consistent with this
cytokine mediating progesterone function.
RANKL and Progesterone-Induced Proliferation. To address whether
RANKL is required for progesterone-induced proliferation, mice
engrafted with RANKL−/− andWT epithelia were stimulated with
progesterone. During the first 24 h, on average 16% of the cells in
both epithelia incorporated BrdU (Fig. 3A), most of which
expressed PR (Fig. 3 B and C). Forty-eight hours after proges-
terone injection, an average of 17% of WT but less than 3% of
RANKL−/− MECs incorporated BrdU (Fig. 3 D–F), suggesting
that RANKL is not required for cell-autonomous proliferation,
but rather paracrine proliferation induced by progesterone.
Analysis of apoptosis in contralateral glands engrafted with
RANKL−/− and WT MECs by caspase 3 staining (Table S1) and
TUNEL assays (Fig. S3) revealed no difference.
It was conceivable that RANKL deletion affected PR signaling;
however, expression of PR (Fig. S4 A and B) and the PR target
genes wnt-4 and calcitonin was comparable (Fig. S4B). Similarly,
cyclin D1 protein levels were independent of RANKL status (Fig.
Fig. 2. Cyclin D1- and progesterone-induced proliferation. (A and D) Mice
engrafted with cyclin D1−/− and WT epithelia were stimulated with proges-
terone for 24 h (A, B, and E) or 48 h (C, D, and F). Histological sections
of contralateral mammary glands engrafted with cyclin D1−/− (A and C) orWT
(B andD) epithelia and stainedwith an anti-BrdU antibody. (Scale bar: 40 μm.)
(E and F) Bar graphs showing BrdU incorporation in cyclin D1−/− andWTMECs
± SEM (n = 3), 1,000 cells counted per mouse.
Fig. 3. Response to progesterone in RANKL−/−MECs. (A–F) Mice engrafted with RANKL−/− or WT MECs stimulated with progesterone for 24 h (A, B, and C) or
48 h (D, E, and F). The percentage of BrdU-incorporating cells ± SEM in contralateral mammary epithelia of three mice after 24 h (A) and 48 h (D) of
stimulation. Open bars, RANKL−/−; black bars, WT MECS; total of 1,000 cells counted in three different sections from each mouse. (B, C, E, and F) Double-
immunofluorescence at 24 h (B and C) and 48 h (E and F) of stimulation. Green, PR; red, BrdU; blue, DAPI. (Scale bar: 40 μm.) Note: at 24 h, RANKL−/− (B) and
WT (C) MECs incorporate BrdU similarly and are PR(+). At 48 h, fewer mutant MECs incorporate BrdU (E) vs. WT (F), and most BrdU-incorporating cells are
hormone receptor negative.






S4C), and RANKL expression levels independent of cyclin D1
status. (Fig. S4 D-H). We concluded that the first wave of pro-
gesterone-induced proliferation is cyclin D1 dependent and
RANKL independent, whereas the second wave is cyclin D1
independent and RANKL dependent.
Ectopic Expression of RANKL in PR−/− Epithelium.To test whether the
paracrine, RANKL-dependent mechanism is sufficient to medi-
ate progesterone function, we ectopically expressed RANKL in
PR−/− epithelium using retroviral vectors and used the infected
cells to reconstitute cleared fat pads. Two months later, the
recipients were mated. At the end of pregnancy, the glands were
analyzed by whole-mount microscopy. As expected, endogenous
control glands showed full alveolar development (Fig. 4A) and
control virus-infected PR−/− cells formed simple ductal systems
(Fig. 4B). In glands reconstituted with RANKL-infected cells,
some sectors had highly branched ductal systems decorated by
alveoli (Fig. 4C andD), and some of these were undistinguishable
from WT control glands (Fig. 4A), indicating that ectopic
RANKL expression rescued the PR−/− phenotype. At the cellular
level, histological sections containing rescued areas showed fat
droplets, a morphological hallmark of milk secretion (Fig. 4E and
F) and expression of the milk protein β-casein (Fig. 4 E and F).
Thus, RANKL expression rescued the PR−/− phenotype with
regard to morphogenesis and differentiation.
In view of the 10–30% efficiency of retroviral infection of pri-
mary MECs, which is usually reflected by a similar extent of
transgene expression in vivo (27), the large extent of rescue in the
grafts with 74% of the grafts showing more than 40% rescue
(Table S2) was surprising. To test whether RANKL is diffusible,
we generated a retrovirus expressing both RANKL and GFP. In
glands reconstituted with PR−/− MECs infected with this virus,
GFP expression overlapped with areas of rescue (n = 10) (Fig. 4
G–I), indicating that RANKL confers a growth advantage to the
MECs expressing it and their immediate neighbors.
Immunohistochemistry on PR−/−MECs infected with the retro-
virus expressing both RANKL and GFP revealed that BrdU-
incorporating cells are frequently found next to ectopic RANKL-
expressing cells, indicating that RANKL indeed elicits proliferation
by a paracrine mechanism (Fig. 4K). Similarly, colabeling of mam-
mary glands from WT females at day 12.5 of pregnancy revealed
dissociation of BrdU incorporation and RANKL expression (Fig.
4L), with RANKL expressing cells frequently as direct neighbors of
BrdU-incorporating cells (Fig. 4L Right). Thus, RANKL elicits
proliferation by a paracrine mechanism.
Systemic Modulation of Proliferation in the Mammary Gland. To
assess whether proliferation of MECs can be induced by systemic
RANKL administration, we injected PR−/− females with
recombinant RANKL (rRANKL). In rRANKL-treated mice,
14% of the MECs incorporated BrdU versus 4% in control-
injected mice (Fig. 5A). Next, we sought to block the interaction
between RANKL and its receptor by administering the decoy
receptorOPG. Injection of rOPGresulted in 54% inhibition of the
progesterone-induced proliferation (Fig. 5B). Double immuno-
histochemistry revealed thatmost of the cells that proliferate in the
presence ofOPGarePR(+) (Fig. 5C). Thus, systemic interference
with RANKL signaling affects proliferation of MECs in vivo.
Discussion
The present study shows that progesterone elicits proliferation in
the mammary epithelium by two distinct mechanisms. First, a
subset of PR(+) cells proliferates by a cyclin D1-dependent
mechanism. Second, a large number of PR(−) cells proliferate by
a RANKL-dependent mechanism. These findings, with exper-
imental hormone stimulation, are consistent with studies under
physiologic conditions in different species showing that most
proliferation occurs in hormone receptor-negative cells (12–14).
Approximately 20% of all PR(+) MECs proliferated during
the first 24 h of hormone stimulation, prompting the question
whether proliferation is a stochastic event or whether distinct
Fig. 4. RANKL is sufficient to mediate PR function
in the mammary epithelium. (A–D) Whole-mount
micrographs of mammary glands from WT hosts
postpartum. (A) Endogenous gland showing highly
branched ductal system with dilated alveoli. (B)
Gland engrafted with PR−/− epithelium infected
with control virus. Note the simple ductal system.
(Scale bar: 300 μm.) (C and D) Two representative
mammary glands engrafted with PR−/− MECs infec-
ted with a retrovirus expressing RANKL showing
extensive alveologenesis (C) or PR−/− phenotype in
one area (arrow) next to a fully developed sector
(arrowhead) (D). (E and F) Histological sections of
postpartum mammary glands stained with an anti-
β-casein antibody, gland engrafted with PR−/− MECs
infected with a retrovirus expressing RANKL (E), and
endogenous control gland (F). Note the presence of
fat droplets and β-casein expression in both WT
epithelium and PR−/− MECs expressing ectopic
RANKL. (Scale bar: 40 μm.) (G–I) Stereomicrographs
of a mammary gland reconstituted with PR−/− MECs
expressing ectopic RANKL and GFP. The sector
highlighted in G is magnified in H; same sector
shown with a fluorescent image taken before tissue
processing (I). Note: area of rescue coincides with
GFP expression. Areas showing the PR−/− phenotype
(arrows; G) do not express detectable levels of GFP
(G). (Scale bar: 1 mm.) (H and I) 400 μm. (K) Double
immunofluorescence for GFP (green) and BrdU (red) on mammary gland reconstituted with PR−/− MECs expressing ectopic RANKL and GFP. Blue, DAPI. Note:
BrdU incorporation in MECs adjacent to cells expressing viral GFP. (L) Anti-RANKL (green) and BrdU (red) immunofluorescence of histological sections of
mammary glands from WT female at day 12.5 of pregnancy. Note: BrdU incorporation in MECs adjacent to cells expressing RANKL. (K and L Right) Zoom of
marked area. (Scale bar: 40 μm.)
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populations of PR(+) cells exist, some with a higher pro-
liferation potential and some more differentiated. It is tempting
to speculate that the BrdU incorporating PR(+) cells represent
hormone receptor-positive stem cells, identified as label retain-
ing epithelial cells (LREC) that incorporate label during
pubertal ductal elongation and proliferate again upon hormonal
stimulation during adulthood (30, 31), and that these cells may
be expressing integrin β3 (CD61), a marker for luminal pro-
genitor cells, some of which express ERα (32).
Our finding that cyclin D1 expression is not affected by dele-
tion of RANKL in the mammary epithelium of virgin mice is in
line with observations on pregnant RANKL−/− mice (33). Yet,
cross-talk between progesterone and RANKL signaling with
cyclin D1 may occur at the level of posttranslational mod-
ification. Cyclin D1 function was shown to be controlled by
phosphorylation on threonine-286 by GSK3-β (34), and IκB
kinase phosphorylates the steroid receptor coactivator (SRC)-3
(35), which is an important coactivator of PR (36).
Cyclin D1 has been shown to be required in MECs for alveolar
development (37) downstream of PrlR signaling and IGF-2 (27).
Whether the block in alveologenesis is related to the failure of at
least some PR(+) cells to divide in response to progesterone or
whether it reflects a distinct function of cyclin D1 in MECs
remains to be addressed.
Previous overexpression studies of both RANKL (18) and its
receptor (19) indicated that RANK signaling is strongly mito-
genic in MECs both in vivo and in vitro. Observations in 3D
cultures pointed to a synergism between RANKL and hepatocyte
growth factor (HGF) in eliciting proliferation of myoepithelial
cells (38). Here, we provide genetic evidence that RANKL is
required for the proliferation of PR(−) MECs and sufficient to
rescue the phenotype of PR−/−MECs, consistent with the finding
that ectopic expression of RANKL elicits pregnancy-related
morphogenetic changes in virgin mice (18). We reported pre-
viously that wnt-4 is required for progesterone-induced side
branching (26). How RANKL and wnt-4 interact, and whether
they are coexpressed in the same PR-positive cells, remains to
be addressed.
RANKL signaling may be directly or indirectly mitogenic.
BAFF/BLyS and CD40L/CD144 also belong to the TNF family—
the former induces direct proliferation of B cells, possibly through
TRAF2-mediated activation of MEKK1, JNK, AP1, and up-
regulation of cyclinD2 (39), whereas the latter indirectly promotes
mitogenic signals originating from the B-cell receptor by promot-
ing survival (40). RANKL was shown to trigger nuclear trans-
locationof Id2,which in turn resulted in the down-regulationof the
cell-cycle inhibitor p21 and proliferation in primary MECs (33).
Breast cancer risk correlates with the number of menstrual
cycles a woman experiences, and cell proliferation occurs during
the luteal phase of the menstrual cycle when progesterone levels
are high, suggesting a link between progesterone exposure and the
disease. Similarly, studies on women on hormone replacement
therapy showed that concomitant administration of estrogens and
progesterone results in increased breast cancer incidence,
whereas administration of estrogen only did not have significant
effect (41). Our finding that progesterone-induced proliferation
can be inhibited by administering OPG may have important
implications if RANKL signaling should have a similar role in the
human breast. Clinical trials to test the utility of anti-RANKL
agents in the therapy of bone erosion diseases such as osteopo-
rosis, rheumatoid arthritis, and multiple myeloma are ongoing
(42); might it turn out that these agents interfere with pro-
liferation, in the breast epithelium possibly in a subset of patients,
and protect against breast cancer?
Materials and Methods
Mice. GFP transgenic, RANKL, PR, and cyclin D1 mutant mice (3, 25, 43, 44)
were bred in C57Bl6 or 129SV/C57Bl6 genetic background. Transplantation
and mammary gland whole mounts were performed as described (5).
Hormone and BrdU Treatments. Ten-week-old female mice were ovariectom-
ized and injected 10 days later s.c. with 17β-estradiol (Sigma; 4 ng/g body
weight) in tocopherol-stripped corn oil (MP Biomedicals). Twenty-four hours
later, vehicle, 17β-estradiol, or 17β-estradiolandprogesterone (Sigma; 100μg/g
body weight) were injected. For continuous stimulation, both steroids were
injected every 24 h. BrdU (Sigma; 30 μg/g body weight) was injected either
every 3 h for 24 h, or as bolus 2 h before sacrifice.
Injection of recombinant RANKL and OPG. HumanOPG (amino acids 1–202)was
fused at the N terminus of hIgG-Fc, expressed, and purified as described (45).
The receptor-binding domain of mRANKL was fused at the C terminus to
hIgG-Fc and purified as described (46). Eight micrograms of Fc-RANKL in PBS
were administered intravenously, and BrdU was injected every 6 h for 72 h.
Twelve-week-old femalemicewere ovariectomized and injected 10 days later
s.c. with 17β-estradiol and 24 h later with progesterone (100 μg/g body
weight). Two hours and 24 h later, mice were injected intraperitoneally with
OPG (2.4 μg/g of body weight) in PBS. BrdU was injected every 6 h for 48 h.
Fig. 5. Systemic manipulation of RANKL signaling affects the mammary
epithelium. (A) Twelve-week-old PR−/− females were injected i.v. with either
8 μg of Fc-RANKL or PBS. BrdU was administered continuously for 72 h. BrdU-
incorporating cells ± SEM; 1,200 cells were counted per mouse (n = 6), rep-
resenting two independent experiments. (B and C) WT females were
stimulated with progesterone and treated either with PBS or OPG. (B) BrdU
incorporation in MECs is plotted ± SEM. Open bars, PBS treated (n = 9); filled
bars, OPG treated (n = 12); three independent experiments were performed.
(C) Double immunofluorescence of histological sections from mammary
glands stimulated with progesterone and treated with PBS (Left) or OPG
(Right). Green, PR; red, BrdU; blue, DAPI; bottom, overlay. Note: most BrdU
(+) MECs in OPG-treated animals are PR(+).






Histological Examination and Immunohistochemistry. Glands fixed with 4%
paraformaldehyde were paraffin embedded. We stained 4-μm sections with
anti-BrdU (1:300) (Oxford Biotechnology; OBT0030), anti-GFP (1:4,000)
(Molecular Probes; A6444), anti-PR (1:400) (Neomarkers; SP2), and anti-
RANKL (1:200) (R&D Systems) overnight at 4 °C after antigen retrieval in
citrate buffer and revealed with Vectastain Elite kit (Vector Laboratories).
RANKL was detected using a TSA Signal Amplification System (PerkinElmer).
Pictures were acquired with a Leica DM2000 microscope and Pixelink PL-
A622C camera, and Zeiss Axioplan 2-imaging fluorescence microscope with
Axiocam MRm camera.
Retroviral Production and Cell Infection. ThemRANKL coding region (GenBank
accession no. AB022039) was extracted from pCR3-RANKL subcloned via
Bluescript intoMSCV (47) or PINCO (48). High-titer retrovirus was produced as
described (49).
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